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Medication with anticholinergic action is associated with potentially serious adverse effects in older 
people. We present an evaluation of a novel anticholinergic burden scale introduced into routine 
practice in older adult services in South London and Maudsley (SLaM) NHS Foundation Trust. Our 
aim was to assess whether this tool improved the accurate identification of anticholinergic 
medication and guided safer prescribing in cognitively vulnerable older people.
Results
The introduction of the AEC tool into clinical practice led to an increase in the identification and 
reporting to GPs of anticholinergic medication from 11% to 85% of cases (p=0.0015). 
Clinical implications 
Application of the AEC tool led to improved detection of anticholinergic medication and advice to 
primary care on when a medication review is necessary. This is an important step towards improving 
the safety of prescribing in this patient group.





Medicines with an anticholinergic effect are associated with an increased risk of cognitive decline, 
dementia and death in older adults1,2,3,4. Anticholinergic medication has also been shown to oppose 
the action of acetylcholinesterase inhibitors and therefore their clinical efficacy5,6.
NICE guidance on dementia7 emphasises the importance of assessing anticholinergic burden in 
cognitively vulnerable older people using an appropriate assessment tool. It recommends that when 
assessing people for cognitive impairment or dementia, a medication review should be conducted to 
identify drugs that may cause cognitive impairment. An NHS England dementia diagnosis and 
management resource for GPs recommends that where possible, drugs with a strong anticholinergic 
effect should be stopped or substituted for drugs with less anticholinergic activity8.
A number of anticholinergic scales already exist and have been developed in order to classify drugs 
according to their anticholinergic risk. These were generally based on the subjective experience of 
assessors and usually dependent on the drug’s general potency to muscarinic receptors9,10. A 
classification system was developed by Bishara et al11 to identify the anticholinergic effect 
specifically on cognition (AEC) for medications commonly used in the elderly. The development of 
the AEC scale was evidence-based and used transparent systematic methodology to evaluate a large 
number of medications, whilst taking into account not only the drug’s affinity for muscarinic 
receptors, but also its potential to cross the blood brain barrier and previous reports on its influence 
on cognitive impairment. 
This tool is designed to be used in health care settings to support clinicians to identify and manage 
anticholinergic medication for patients with cognitive impairment. The AEC tool classifies medication 
according to a “traffic light” system, giving drugs an individual score of 0,1,2 or 3. A score of 0 means 
the medication has no anticholinergic effect on cognition and a score of 3 has the most effect. The 
individual scores of all the medications that a patient is taking are then added together to give a 
total AEC score.  It is recommended that those with cognitive impairment who are on medication 
with an individual AEC score of 2 or more, or have a total AEC score of 3 or more, have a medication 
review so that the offending drugs can be withdrawn or switched to a safer alternative. The aim is to 
reduce the total AEC score to the lowest possible score.
Aim
Our aim was to determine whether the introduction of the AEC tool into routine practice in older 
adult services would improve the identification of medicines with a significant anticholinergic effect 
on cognition and lead to appropriate advice given to the patient’s General Practitioner on which 
drugs to review. It is hoped that such an intervention would result in an overall reduction in 
anticholinergic burden in patients and thus improve prescribing safety.  We introduced the AEC scale 
into three older adult services across South London and Maudsley (SLaM) NHS Foundation Trust to 
assess its role in the identification of anticholinergic drugs and subsequent advice given to primary 
care regarding medication reviews. 





Current practice at the time of the study: New patients referred to the Southwark and Lambeth 
Memory Service, are assessed by one member of the multidisciplinary team (MDT). The MDT consists 
of registered mental health nurses, clinical support workers, clinical psychologists, social workers, 
psychiatry trainees and a consultant psychiatrist. Assessments are completed using a document 
template which forms the basis of a report which is sent to the GP and uploaded onto the patient’s 
electronic health records. This includes information in relation to the clinical history and examination, 
diagnosis, the patient’s management plan and recommendations to the GP. All new assessments are 
discussed in the weekly MDT meeting. Prior to the introduction of the AEC tool, there was no formal 
template for assessing the anticholinergic burden of patients’ medications. 
Before introducing the intervention, retrospective baseline systematic sampling was used to identify 
70 new patients assessed in the Southwark and Lambeth Memory Service over a three month period 
from January 2016. Data was collected by two psychiatry trainee doctors and included information 
retrieved from the patient’s electronic patient record (EPR), including the patient’s diagnosis, the 
patient’s full medication list and the individual drug AEC scores. From this, the total AEC score was 
calculated. Information was also gathered on whether there was documentation that the 
anticholinergic medications and their potential anticholinergic burden had been identified, and 
whether this was communicated to the GP with appropriate advice.  
The intervention: In October 2016, the AEC scale was then introduced into three separate older adult 
services across SLaM. SLaM is one of Europe’s largest healthcare providers for mental health and 
dementia and serves a local population of 1.3 million people. The following teams were included in the 
study; Southwark and Lambeth Memory Service (SLMS), Lewisham Memory Service and Lewisham 
Care Home Intervention Team (CHIT). A CHIT was included as it was considered that these teams are 
ideally placed to review anticholinergic medication in patients with dementia. A training session was 
provided to educate all staff conducting new assessments for patients on how to use the AEC scale, 
along with guidance on how to communicate high risk drugs to the GP, whilst providing appropriate 
advice on which drugs to review. The assessment document template was updated to include, under 
the management plan, a standard communication to the GP informing them about the quality 
improvement project and a section to document the patients’ individual drug and total AEC scores. 
Depending on the AEC scores, appropriate advice on whether a medication review was deemed 
necessary or not then followed. If the individual AEC score for a drug was 2 or more, or if the total AEC 
score was 3 or more the advice to the GP was “we recommend that the following drugs be reviewed 
so as to reduce the anticholinergic burden on cognition”. If the total AEC score was under 3 and there 
were no individual drugs with an AEC score of 2 or more, then the advice was ‘there is no need for 
further review’. This advice is based on similar scales such as the Anticholinergic Cognitive Burden 
(ACB) scale that has shown that this scoring system reflects the potential clinical implications3.
Following the intervention, systematic sampling identified 98 patients newly assessed in the 
Southwark and Lambeth Memory Service from 1st September 2016 to 31st December 2016. Data 
were collected by a psychiatry trainee doctor, a consultant psychiatrist and a consultant pharmacist.   
The admission documents for the patients identified were again examined to determine whether 
anticholinergic medication had been correctly identified and communicated to the GP.  Post-
intervention data was also collected from the Lewisham Memory Service and Care Home Intervention 
Team (CHIT) by their designated pharmacist, so as to assess whether the intervention could easily be 
incorporated into the practice of other teams as well.





In the Southwark and Lambeth Memory Service, pre intervention/baseline results showed that 20 
patients (29%) were on anticholinergic medication. Similarly, post intervention results showed that 30 
patients (30%) were on medication with an anticholinergic effect on cognition. Eleven patients from 
the pre intervention sample (16%) and 13 patients from the post intervention sample (13%) were on 
medications with an individual AEC score of 2 or more (Table 1).
Clinicians had identified 4 out of the 11 patients (36%) from the pre intervention sample i.e. those 
prescribed drugs with an individual AEC score of 2 or more (Table 1). The identification of an 
anticholinergic burden (score of 2 or more on the AEC) improved to 11 out of the 13 (85%) following 
the study intervention.
Table 1






Patients taking medication with an individual AEC score of 
2 or more
11 (16) 13 (13)
Documentation of identification of drugs with an 
individual AEC score of 2 or more, n (%)
4 (36) 11 (85)
AEC, anticholinergic effect on cognition
Nine patients (13%) from the pre intervention sample and 13 patients (13%) from the post 
intervention sample had a total AEC score of 3 or more (Table 2). Only 1 out of the 9 patients (11%) 
had their total AEC score of 3 or more identified and communicated to the GP in the pre intervention 
sample. Identification and communication of total AEC scores of 3 or more improved with the 
intervention. Eleven of the 13 post intervention patients (85%) had their total AEC score of 3 or more 
identified and communicated to the GP. A chi-squared (Fisher’s exact) test showed that this 
improvement was statically significant (p= 0.0015). 
However, of the patients whose AEC scores were communicated to the GP, two patients (15%) had 
their total scores calculated incorrectly (errors in the AEC scores and calculations were also noted for 
patients where the total score was less than 3). Reasons for the miscalculations included medications 
not being correctly identified due to having multiple names (e.g. dosulepin’s score was considered not 
known; however, it was listed on the AEC scale as having a score of 3 under the name dothiepin), 
medications’ AEC score not being correctly identified on the scale and medications being included 
twice in the calculation. For the remaining 2 patients (15%) the total AEC score of 3 or more was not 
identified and not communicated to the GP for reasons unknown. 













Patients with total AEC score of 3 or more 9 (13) 13 (13)
Documentation that patients with total AEC score of 3 or more 
were identified and score communicated to GP
- Anticholinergic burden communicated to the GP
- Total AEC score communicated correctly
- Total AEC score communicated but calculated incorrectly








AEC, anticholinergic effect on cognition; GP, general practitioner
Figure 1 
Pie charts showing the improvement of identification and communication to the GP of patients on 
medication with a total anticholinergic burden of 3 or more 
Was Total AEC score of ≥ 3 communicated to the GP?
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Post intervention data collected from the Lewisham teams showed 40% of patients from the CHIT 
team and 29% of patients from the memory service were on anticholinergic medication.  The high rate 
of identification of anticholinergic medication with the use of the AEC tool was also reflected in these 
teams using the same methods described above. Post intervention results showed that the 
anticholinergic burden had been communicated to the GP for 100% (7 out of 7) of patients with a total 
AEC score of 3 or more in the CHIT team and for 86% (19 out of 22) of patients in the memory service. 
Discussion
This study provides evidence that, without a structured tool, the identification of medications with an 
anticholinergic effect on cognition and subsequent communication with advice to primary care was 
poor. With the introduction of the AEC tool and inclusion of an anticholinergic burden section in the 
assessment document, the identification and communication with appropriate advice to the GP 
regarding these drugs greatly improved.  This study suggests that with a brief training session using 
the AEC tool, identification of medications with clinically significant high AEC scores are identified and 
communicated to the GP in 85-100% of cases. This is a significant improvement from pre intervention 
results showing that in only 11-36% of cases, identification of anticholinergic burden was noted and 
communicated to the GP.  
Where a psychotropic medication is causing a cognitive burden, this can represent a challenge, 
particularly if a patient has had a stable mental state over a sustained period of time.  The mental 
health team may be able to suggest an alternative treatment in such situations and consider the risks 
versus benefits of switching.  
Limitations
Our intervention greatly improved the identification of and communication to GPs of anticholinergic 
medications. However, at times, the AEC calculations provided to the GP were incorrect.  
Miscalculations of the AEC score were secondary to human error (drugs being included twice in the 
calculation or confusion regarding drug names leading to misidentification of the AEC score).  These 
findings alerted us to the importance of having an electronic version the AEC scale, so as to eliminate 
such errors arising from misidentification of drugs from the list or simple calculation errors when 
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The results of this quality improvement programme led to the development of “Medichec”; a web-
based and application version of the AEC tool.  This allows practitioners to easily check their patient’s 
medication and the cumulative anticholinergic burden score are automatically calculated. The system 
will identify a drug and its score by any of the names listed in the British National Formulary (BNF). It 
alerts the practitioner as to which drugs need to be reviewed and gives advice on how to interpret the 
score in order for them to be communicated to the GP.  Medichec only uses generic names and 
prompts the user when a trade name is used.  It contains over 2000 medications and is now being 
used across SLaM’s older adult services and in other areas of the UK. The AEC tool is available online as 
a free resource at http://www.medichec.com. An Android application is also available, with plans for 
an Apple application to follow shortly. Plans are also underway to see whether Medichec can be 
incorporated into the GP health record systems so as to improve accessibility and safer prescribing for 
cognitively vulnerable patients in primary care. 
Figure 2
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